Literature DB >> 17346853

Expression of adrenomedullin2/intermedin in human brain, heart, and kidney.

Ryo Morimoto1, Fumitoshi Satoh, Osamu Murakami, Kazuhito Totsune, Takashi Suzuki, Hironobu Sasano, Sadayoshi Ito, Kazuhiro Takahashi.   

Abstract

Adrenomedullin2/intermedin (AM2/IMD) is a novel member of the calcitonin/calcitonin gene-related peptide (CGRP) family. In the present study, we developed a specific radioimmunoassay of human AM2/IMD. Expression of AM2/IMD was studied in the human brain, pituitary, heart and kidney obtained at autopsy by radioimmunoassay and immunocytochemistry. Immunoreactive-AM2/IMD was detected by radioimmunoassay in human brains (range; 0.163-1.495 pmol/g wet weight), pituitaries (4.46+/-0.689 pmol/g wet weight, mean+/-S.E.M, n=3), left ventricles of hearts (0.251+/-0.0321 pmol/g wet weight, n=4), kidneys (3.49+/-1.18 pmol/g wet weight, n=5), and plasma obtained at healthy subjects (24.7+/-1.78 pmol/l, n=3). Reverse-phase high performance liquid chromatography showed that immunoreactive-AM2/IMD in human brain, kidney and plasma extracts were eluted in the position of authentic AM2/IMD. Additional peaks eluted earlier were found in the brain tissue and plasma. Immunocytochemistry showed that immunoreactive-AM2/IMD was localized in paraventricular and supraoptic nuclei of hypothalamus, anterior and posterior lobes of pituitary, cardiomyocytes, pericardial adipocytes, vascular endothelial cells of pericardial veins, and vascular smooth muscle cells of coronary arteries and renal arterioles as well as in renal tubular cells. The present study has shown expression of AM2/IMD in various types of cells in the central nervous system and the cardiovascular system, and suggested possible (patho)physiological roles of AM2/IMD in these systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346853     DOI: 10.1016/j.peptides.2007.01.018

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  20 in total

Review 1.  Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases.

Authors:  Song-Yang Zhang; Ming-Jiang Xu; Xian Wang
Journal:  Br J Pharmacol       Date:  2017-05-16       Impact factor: 8.739

Review 2.  Adrenomedullin 2/intermedin in the hypothalamo-pituitary-adrenal axis.

Authors:  Kazuhiro Takahashi; Ryo Morimoto; Takuo Hirose; Fumitoshi Satoh; Kazuhito Totsune
Journal:  J Mol Neurosci       Date:  2010-07-02       Impact factor: 3.444

3.  AM₁-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury.

Authors:  David Bell; Malcolm Campbell; Matthew Ferguson; Leah Sayers; Liz Donaghy; Anna O'Regan; Victoria Jewhurst; Mark Harbinson
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

Review 4.  The pharmacology of adrenomedullin 2/intermedin.

Authors:  Yanguo Hong; Debbie L Hay; Remi Quirion; David R Poyner
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

5.  Intermedin/adrenomedullin 2 polypeptide promotes adipose tissue browning and reduces high-fat diet-induced obesity and insulin resistance in mice.

Authors:  H Zhang; S-Y Zhang; C Jiang; Y Li; G Xu; M-J Xu; X Wang
Journal:  Int J Obes (Lond)       Date:  2016-01-20       Impact factor: 5.095

6.  Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation.

Authors:  Yanhong Wang; Jihua Tian; Haixiu Guo; Yang Mi; Ruijing Zhang; Rongshan Li
Journal:  Clin Exp Med       Date:  2015-04-28       Impact factor: 3.984

7.  Adrenomedullin 2 Enhances Beiging in White Adipose Tissue Directly in an Adipocyte-autonomous Manner and Indirectly through Activation of M2 Macrophages.

Authors:  Ying Lv; Song-Yang Zhang; Xianyi Liang; Heng Zhang; Zhi Xu; Bo Liu; Ming-Jiang Xu; Changtao Jiang; Jin Shang; Xian Wang
Journal:  J Biol Chem       Date:  2016-09-12       Impact factor: 5.157

8.  Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress.

Authors:  Makoto Hagiwara; Grant Bledsoe; Zhi-Rong Yang; Robert S Smith; Lee Chao; Julie Chao
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-01

9.  Neuroprotection of Intermedin Against Cerebral Ischemia/Reperfusion Injury Through Cerebral Microcirculation Improvement and Apoptosis Inhibition.

Authors:  Xin Guo; Jie Yuan; Meixi Li; Meng Wang; Peiyuan Lv
Journal:  J Mol Neurosci       Date:  2020-09-10       Impact factor: 3.444

Review 10.  Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.

Authors:  D Bell; B J McDermott
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.